OncoSec: Rises as gene delivery device gets CE Mark

OncoSec Medical Incorporated

14/04/2021 17:09

** Immunotherapy developer's shares  ONCS.O  rise 2.3% to
$4.72 
    ** Co receives CE Mark for its gene delivery device GenPulse
 urn:newsml:reuters.com:*:nPn1lQfD1a
    ** CE mark indicates conformity with health, safety and
environmental protection standards for products sold within
European Economic Area 
    ** The device, part of ONCS's platform for treating tumors,
applies short electric impulses to a tumor, causing pores to
open in membrane of cancer cells and increasing uptake of
anti-cancer agents into these cells
    ** Co says the CE mark will enable commercialization of
GenPulse in EU

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))